Kathy Nielsen

In order to realise the full potential of Australia’s innovation opportunities, new approaches are required to take discoveries through the process of translation and early commercialisation - the so-called ‘valley of death’. It is precisely this ‘valley’ that a newly launched $80 million enterprise, BioCurate Pty Ltd, aims to traverse in the field of biomedical drug development. BioCurate has been formed as a joint venture between two leading Australian Universities, the University of Melbourne and Monash University. As an independent venture catalyst, BioCurate will target this critical phase of development and provide the commercial focus, expertise and funding, necessary to boost successful translation and commercialisation.